Biochemist Peter Kim receives $18 million grant to develop broadly efficient antiviral vaccine

The Coalition for Epidemic Preparedness Innovations has awarded a group led by Peter Kim, PhD, the Virginia and D.Okay. Ludwig Professor in Biochemistry, a four-year, $18 million grant to develop vaccines that might provide broad safety from filoviruses, a household of viruses that features the extremely deadly Ebola and Marburg.

CEPI, based mostly in Oslo, Norway, is a global group with the purpose of accelerating the event of vaccines and different biologic countermeasures in opposition to epidemic or pandemic threats.

Kim and his fellow researchers will use the award to design and take a look at new vaccine candidates that might present all-in-one safety in opposition to at the moment recognized filoviruses in addition to these which are restricted to nonhuman hosts however may soar from animals to people.

“We aim to create a single, broad-spectrum vaccine that will protect against three viruses causing frequent outbreaks in Africa — Zaire Ebola virus, Sudan Ebola virus and Marburg virus — which, collectively, have an average fatality rate of around 50%,” mentioned Kim, the mission’s principal investigator.

The researchers will use synthetic intelligence to design immunogens — the substances in a vaccine that provoke an immune response — that, they hope, will shield in opposition to a couple of filovirus. These immunogens shall be introduced on a ferritin-based protein-nanoparticle framework to create a variety of candidates that shall be examined in laboratory and animal research. The researchers will quickly advance essentially the most promising vaccine candidate to the purpose the place it is able to rapidly enter medical trials ought to an unknown filovirus outbreak emerge.

The ferritin nanoparticle-based vaccine is favorable to be used in low- and middle-income nations because it doesn’t require frozen storage, which might restrict entry in low-resource settings. It has already been examined in Phase I medical trials for influenza and COVID-19 vaccines, which had been proven to be protected.

“Our goal is to make the vaccine stable enough that it will maintain stability without requiring freezer storage and that it will be inexpensive to manufacture,” Kim mentioned.